Pilot Testing A Theory-Driven Self-Management Intervention for Chronic Musculoskeletal Pain

Not Applicable

Completed

• Conditions: Chronic Musculoskeletal Pain
• Interventions: Device: Virtual Auricular Point Acupressure (APA); Other: Usual Care; Other: In-Person Training

• Registration Number: NCT05020470
• Lead Sponsor: Johns Hopkins University

Brief Summary

The proposed randomized control trial will evaluate auricular point acupressure (APA) treatment administered by the participant themselves with the use of a phone app on chronic musculoskeletal pain (CMP) outcomes.

This study will randomly assign participants into three groups: (1) Self-guided mAPA (S-mAPA), (2) In-Person Training + mAPA (IP-mAPA), and (3) Usual Care Control (UC). EMA will be used to assess momentary pain outcomes and APA adherence.

Data will be collected at pre- (T1), post-completion of intervention (T2), follow-ups at post 1M- (primary endpoint) (T3), 2M (T4), and 3M (secondary endpoint, long-term sustained effect) (T5) for a total of four assessments.

Detailed Description

Chronic musculoskeletal pain (CMP) is the most common self-reported and clinically diagnosed pain condition in the US and costs up to $635 billion annually. Analgesics/opioids are the most common treatments utilized by patients with CMP, however, unnecessary opioid use has resulted in the current opioid epidemic. The Institute of Medicine recommended guidelines for non-pharmacologic, self-management strategies to manage pain. However, these guidelines have not been broadly implemented due to time constraints among healthcare providers, accessibility, patient's beliefs/motivations, and high cost/insurance coverage, especially among socioeconomically disadvantaged and vulnerable patients.

Auricular point acupressure (APA), a non-invasive procedure, provides acupuncture-like stimulations on ear points using small pellets instead of needles to self-manage pain. The investigator's interdisciplinary team has accumulated extensive evidence (11 clinical trials) supporting the efficacy of interventionist-administered APA to manage pain. The randomized clinical trial (RCT) comparing APA to sham APA demonstrated: (1) Significant rapid and sustained effect: APA resulted to ≥38% rapid pain relief among participants at three minutes post-APA; \>44% pain relief and \>28% improved physical function at follow-up after 4-weeks APA; (2) Reduced use of medications: After 4-weeks of APA, ≥60% of participants reported less use of pain medications; and (3) Significant impact on physiological measures: APA controls pain through blocking pro-inflammatory cytokines (IL-1β, IL-2) and modulating nerve sensitivity. No adverse effects from APA were reported.

The investigator's long-term goal is to eliminate pain care disparities and reduce society's reliance on opioids to manage pain. Leveraging technology, the proposed study will help advance mAPA, a novel, easy-to-initiate, rapid, safe, and non-pharmacologic tool incorporated in a self-management plan to manage pain in real-world settings. The proposed intervention promises to provide important and timely information to advance a non-opioid and self-managed pain treatment.

Study Timeline

• Study First Submitted: 2021-08-19
• Study First Submitted QC: 2021-08-19
• Study First Posted: 2021-08-25
• Study Start: 2021-09-22
• Primary Completion: 2022-08-11
• Study Completion: 2022-08-11
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-08
• Last Update Posted: 2023-06-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

• Adults 18 years of age or older.
• Receiving outpatient pain treatment for CMP condition (e.g., pain in the back, hip, knee, upper extremity, lower extremity, neck, pelvic, headache/migraine).
• Chronic pain ≥ 4 on a scale of 0-10 point numerical pain, persisting for at least 3 months or has resulted in pain on at least half the days in the past 6 months.

Read More

Exclusion Criteria

• Disease that might confound therapeutic effects or explanation of outcomes, i.e., infection, malignant tumors, or autoimmune diseases.
• Severe ear skin issues.
• Use of some types of hearing aids (size may obstruct the placement of seeds)
• Concurrent major psychiatric disorder (i.e., participant self-report).
• Pregnant women will be excluded from the study based on the self-reported data.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
In-Person Training + mAPA (IP-mAPA)	In-Person Training	Participants will receive one in-person training after baseline data is collected and then will self-administer APA on the same schedule with weekly telecommunication as those in the mAPA group.
Self-guided mAPA (S-mAPA)	Virtual Auricular Point Acupressure (APA)	S-mAPA group will be provided with instructions so that participants can learn to self-administer APA weekly for four weeks and then followed by weekly telecommunication for Q \& As.
In-Person Training + mAPA (IP-mAPA)	Virtual Auricular Point Acupressure (APA)	Participants will receive one in-person training after baseline data is collected and then will self-administer APA on the same schedule with weekly telecommunication as those in the mAPA group.
Usual Care Control (UC)	Usual Care	Participants will receive usual care only for their pain; after enrolled, patients will receive weekly telecommunication to control for attention and time. The content of the phone/video call will focus on the pain problem they have and the investigators will provide additional information published by the National Center for Complementary and Integrative Health "Chronic Pain: In-Depth" (https://www.nccih.nih.gov/health/chronic-pain-in-depth) which the investigators used in the R01 study for participants enrolled in the control group

Primary Outcome Measures

Name	Time	Method
Pain intensity	Up to 4 months	The Brief Pain Inventory-short form (BPI-sf) questionnaire includes assessment of pain location and multiple aspects of severity of pain, numbness, tingling, and stiffness, including worst, least, average pain, and present, as well as the interference with daily activities. The Brief Pain Inventory-short form (BPI-sf) has a total score ranging from 0 to 10 with higher scores indicating more pain.
Pain Interference	Up to 4 months	The Roland Morris Disability Questionnaire (RMDQ), 24-item measure, was used to assess the impact of back pain on their daily functioning. The score ranged from 0 (no disability) to 24 (maximum disability).
Physical Function	Up to 4 months	The Oswestry Disability Index (ODI) was used to measure a participants impairment and quality of life on 10 items with 0-5 point scales. Each section is scored on a 0-5 scale, 5 representing the greatest disability. The index is calculated by dividing the summed score by the total possible score, which is then multiplied by 100 and expressed as a percentage. Thus, for every question not answered, the denominator is reduced by 5; a lower score indicates less disability.

Secondary Outcome Measures

Name	Time	Method
Fear-Avoidance	Up to 4 months	It is measured by Fear-avoidance beliefs questionnaire (FABQ) that focuses on participants beliefs about how physical activity and work affect their pain. The questionnaire consists of 16 items in which a participant rates their agreement with each statement on a 7-point Likert scale. Where 0= completely disagree, 6=completely agree. Maximum score of 96; A higher score indicates more strongly held fear-avoidance beliefs. The first 5 questions pertain to physical activity while the remaining 11 pertain to work. The Physical Activity subscale range 0-24 is the sum of items 2-5; the Work subscale, range 0-42 is the sum of items 6, 7, 9-12 and 15.
Positive Outlook	Baseline and 4 months	Pre and post treatment positive outlook effects will be measured via Healing Encounters and Attitudes Lists (HEAL) Positive Outlook scale. The participants will be assessed using a 6-item questionnaire, scored for outlook on life 1 (not at all) - 5 (very much). Score range of 6- 30; A higher score indicates more positive outlook and satisfaction with ones life.
Treatment Satisfaction	Up to 4 months	The participants will be assessed using a 12-item Treatment Satisfaction Questionnaire, with 4 items with scored for treatment difficulty 1 (extremely difficult) - 5 (not difficult), 7 single-choice questions assessing satisfaction and effectiveness of treatment and 3 open-ended questions assessing satisfaction and effectiveness of treatment. Maximum score of 36; A higher score indicates more satisfaction from the treatment.
Pain and Catastrophizing Scale (PCS)	Up to 4 months	The PCS was included to detect exaggerated and negative interpretations of pain. It is a self-report scale that consists of 13 items. Participants were asked to reflect on past painful experiences and to indicate to which degree he/she experienced symptoms such as helplessness or rumination when feeling pain.This is a 0-4 Likert scale (score sum 0-52) with responses ranging from "not at all" to "all the time," and high scores indicate stronger catastrophizing.
Health Related Quality of Life (HRQoL)	Up to 4 months	The WHO Quality of Life-BREF (WHOQOL-BREF), used to measure quality of life. The WHOQOL-BREF, is self-administered, and measures the following broad domains: physical health, psychological health, social relationships, and environment. Each individual item of the WHOQoL is scored from 1 to 5 on a response scale, which is stipulated as a five-point ordinal scale. The measure is calculated by summing the point values for the questions corresponding to each domain and then transforming the scores to a 0-100 point interval. The first two questions of the WHOQOL-BREF do not correspond to a domain, but are meant to provide a global assessment of quality of life. Higher scores in each of the domains correspond to greater perceived quality of life.
Placebo effect	Up to 4 months	Placebo effects will be measured via Healing Encounters and Attitudes Lists (HEAL) Treatment Expectation questionnaire. HEAL is an item bank comprised of 6 domains. The Treatment Expectancy questionnaire consists of 6 items on a 5 point scale - not at all to very much. Score range of 6-30 with higher score indicating better outcome.

Trial Locations

Locations (2)

Johns Hopkins School of Nursing; 🇺🇸 Baltimore, Maryland, United States

University of Nevada, Las Vegas; 🇺🇸 Las Vegas, Nevada, United States